240 related articles for article (PubMed ID: 29233532)
1. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
[TBL] [Abstract][Full Text] [Related]
2. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Cunningham JM; Cicek MS; Larson NB; Davila J; Wang C; Larson MC; Song H; Dicks EM; Harrington P; Wick M; Winterhoff BJ; Hamidi H; Konecny GE; Chien J; Bibikova M; Fan JB; Kalli KR; Lindor NM; Fridley BL; Pharoah PP; Goode EL
Sci Rep; 2014 Feb; 4():4026. PubMed ID: 24504028
[TBL] [Abstract][Full Text] [Related]
4. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Kalachand RD; Stordal B; Madden S; Chandler B; Cunningham J; Goode EL; Ruscito I; Braicu EI; Sehouli J; Ignatov A; Yu H; Katsaros D; Mills GB; Lu KH; Carey MS; Timms KM; Kupryjanczyk J; Rzepecka IK; Podgorska A; McAlpine JN; Swisher EM; Bernards SS; O'Riain C; O'Toole S; O'Leary JJ; Bowtell DD; Thomas DM; Prieske K; Joosse SA; Woelber L; Chaudhry P; Häfner N; Runnebaum IB; Hennessy BT
J Natl Cancer Inst; 2020 Dec; 112(12):1190-1203. PubMed ID: 32413141
[TBL] [Abstract][Full Text] [Related]
6. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
7. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
8. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
9. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.
D'Angelo E; Espinosa I; Felicioni L; Buttitta F; Prat J
Hum Pathol; 2023 Nov; 141():15-21. PubMed ID: 37673346
[TBL] [Abstract][Full Text] [Related]
10. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
[TBL] [Abstract][Full Text] [Related]
11. Acquired
Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
[TBL] [Abstract][Full Text] [Related]
12. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos S; van Diest PJ; Moelans CB
Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
[TBL] [Abstract][Full Text] [Related]
14. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
15. A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
Evans DGR; van Veen EM; Byers HJ; Wallace AJ; Ellingford JM; Beaman G; Santoyo-Lopez J; Aitman TJ; Eccles DM; Lalloo FI; Smith MJ; Newman WG
Am J Hum Genet; 2018 Aug; 103(2):213-220. PubMed ID: 30075112
[TBL] [Abstract][Full Text] [Related]
16. Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer.
Li N; McInerny S; Zethoven M; Cheasley D; Lim BWX; Rowley SM; Devereux L; Grewal N; Ahmadloo S; Byrne D; Lee JEA; Li J; Fox SB; John T; Antill Y; Gorringe KL; James PA; Campbell IG
J Natl Cancer Inst; 2019 Dec; 111(12):1332-1338. PubMed ID: 30949688
[TBL] [Abstract][Full Text] [Related]
17. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.
Hansmann T; Pliushch G; Leubner M; Kroll P; Endt D; Gehrig A; Preisler-Adams S; Wieacker P; Haaf T
Hum Mol Genet; 2012 Nov; 21(21):4669-79. PubMed ID: 22843497
[TBL] [Abstract][Full Text] [Related]
18. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
19. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
[TBL] [Abstract][Full Text] [Related]
20. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
